All therapies targeting CD123 are not created equally, Stemline Therapeutics Inc. CEO Ivan Bergstein told BioWorld after the company reported top-line data confirming that the phase II pivotal trial of SL-401 hit its primary endpoint for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Although other modalities, from CAR Ts to bispecifics, are directed to the interleukin-3 receptor, "you can't necessarily predict the safety and efficacy of a drug just because it hits the same target as another drug," Bergstein said.